一线晚期肺腺癌治疗中 PD-1 抗体联合化疗和抗血管生成药物联合化疗 的对比研究. (Chinese)

Objective: To study the efficacy and safety of PD-1 antibody plus chemotherapy compared with those of antiangiogenic drug plus chemotherapy in the frontline treatment of advanced lung adenocarcinoma with negative driving genes. Methods: We collected data from 141 patients with unresectable stage ⅢB/ⅢC and Ⅳ lung adenocarcinoma with negative driving genes who were treated in the Fourth Hospital of Hebei Medical University from March 2018 to August 2021, and retrospectively studied the efficacy and safety of PD-1 antibody plus chemotherapy and those of antiangiogenic drug plus chemotherapy in frontline clinical application. The primary outcome measure was the progression-free survival (PFS), and the secondary outcome measures were objective response rate (ORR), disease control rate (DCR) and adverse reactions. Results: All of the 141 patients were included in the survival analysis. The median follow-up time was 13.0 months (95% CI: 12.0-14.0). The ORRs of PD-1 antibody plus chemotherapy group (group A) and antiangiogenic drug plus chemotherapy group (group B) were 33.33% and 27.38% respectively; the DCRs of group A and group B were 98.25% and 89.29% respectively, both with no statistical significance. The median PFSs of group A and group B were 8.4 months (95% CI: 7.3-9.9) and 6.9 months (95% CI: 6.1-7.7) respectively with no statistical significance. The results of subgroup analysis showed that the median PFSs of group A were longer than those of group B for stage ⅢB/ⅢC patients and patients with liver or brain metastasis (all P<0.01). The incidence of adverse reactions in group A and group B were 26.32% and 14.29% respectively, and most of the adverse reactions were grade 1-2. Conclusion: Compared with antiangiogenic drug plus chemotherapy, PD-1 antibody plus chemotherapy had the same efficacy in the frontline treatment of advanced lung adenocarcinoma with negative driving genes and the adverse reactions were tolerable. These two therapies could be standard first-line treatments for advanced lung adenocarcinoma with negative driving genes. [ABSTRACT FROM AUTHOR]

目的：探讨 PD-1 抗体联合化疗对比抗血管生成药物联合化疗在晚期驱动基因阴性肺腺癌一线治疗中的疗效和安全 性。方法：收集 2018 年3 月至 2021 年 8 月河北医科大学第四医院收治的141 例不可手术切除的 ⅢB/ⅢC 和 Ⅳ 期驱动基因阴性肺 腺癌患者，回顾性分析 PD-1 抗体联合化疗对比抗血管生成药物联合化疗在一线治疗中的疗效与安全性。主要研究终点为无进 展生存期（PFS)，次要终点为客观缓解率(ORR)、疾病控制率（DCR) 和不良反应。结果：141 例患者均纳入生存分析，中位随访 时间为 13.0 个月（95% CI：12.0～14.0)。PD-1 抗体联合化疗组（A 组) 和抗血管生成药物联合化疗组（B 组)的 ORR 分别为 33.33% 和 27.38%，DCR 分别为 98.25% 和 89.29%，差异均无统计学意义。A 组和 B 组的中位 PFS 分别为 8.4 个月（95% CI: 7.3～9.9) 和 6.9 个月（95% CI: 6.1～7.7)，差异无统计学意义。亚组分析结果显示，ⅢB/ⅢC 期、肝或脑转移患者中，A 组中位 PFS 较B组均延长 （均 P<0.01)。A组和B组不良反应发生率分别为 26.32% 和14.29%，多数为 1~2 级。结论：PD-1 抗体联合化疗对比抗血管生成药 物联合化疗一线治疗晚期驱动基因阴性肺腺癌疗效相当，不良反应可耐受，可成为晚期驱动基因阴性肺腺癌标准一线治疗。 [ABSTRACT FROM AUTHOR]

Copyright of Chinese Journal of Cancer Biotherapy is the property of Editorial Office of Chinese Journal of Cancer Biotherapy and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)